BMD

Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates

Retrieved on: 
Friday, March 8, 2024

JERUSALEM, March 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, today reported financial results and key business updates for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • JERUSALEM, March 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, today reported financial results and key business updates for the fourth quarter and year ended December 31, 2023.
  • Following our December 2023 financing, we expect to have sufficient cash to fund operations through the first half of 2025,” said Miranda Toledano, CEO of Entera.
  • Financial Results for the year Ended December 31, 2023
    As of December 31, 2023, Entera had cash and cash equivalents of $11.0 million.
  • Operating expenses for year ended December 31, 2023 were $8.9 million, as compared to $13.0 million for the year ended December 31, 2022.

Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference

Retrieved on: 
Wednesday, February 28, 2024

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on EDG-5506, an investigational therapy designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies, at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference.

Key Points: 
  • Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on EDG-5506, an investigational therapy designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies, at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference.
  • The conference will take place at the Hilton Orlando in Orlando, FL from March 3-6, 2024.
  • Posters will be showcased during the Networking & Poster Reception in the Exhibit Hall on Monday, March 4, 2024, from 6 – 8 PM ET.
  • The Edgewise presentation and posters will be available on the Edgewise website when they are presented.

Boise Cascade Company Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Tuesday, February 20, 2024

For the year ended December 31, 2023, sales decreased $1,464.9 million, or 19%, to $6,178.7 million from $7,643.6 million in 2022.

Key Points: 
  • For the year ended December 31, 2023, sales decreased $1,464.9 million, or 19%, to $6,178.7 million from $7,643.6 million in 2022.
  • Boise Cascade ended fourth quarter 2023 with $949.6 million of cash and cash equivalents and $395.9 million of undrawn committed bank line availability, for total available liquidity of $1,345.5 million.
  • For the year ended December 31, 2023, the Company paid common stock dividends of $346.5 million, or $8.70 per share.
  • For the year ended December 31, 2023, the Company paid $6.4 million for the repurchase of 75,678 shares of our common stock.

Boise Cascade announces retirement of senior executive Tom Hoffmann

Retrieved on: 
Monday, January 15, 2024

Boise Cascade Company (Boise Cascade) (NYSE: BCC) today announced the retirement of Tom Hoffmann, Senior Vice President of Purchasing, Building Materials Distribution (BMD) division, effective March 1, 2024.

Key Points: 
  • Boise Cascade Company (Boise Cascade) (NYSE: BCC) today announced the retirement of Tom Hoffmann, Senior Vice President of Purchasing, Building Materials Distribution (BMD) division, effective March 1, 2024.
  • View the full release here: https://www.businesswire.com/news/home/20240115997907/en/
    Tom Hoffmann, Senior Vice President of Purchasing, Boise Cascade Company (Photo: Business Wire)
    Tom joined Boise Cascade in 1981.
  • Tom holds a bachelor’s degree in business with a dual major in management and marketing from the University of Idaho.
  • “We have been intentional in planning for this transition considering the experience and numerous areas Tom has managed over the years.

NextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury

Retrieved on: 
Thursday, December 21, 2023

The data demonstrated that NC605, a novel anti-Siglec-15 (S15) antibody, prevented bone loss, but more importantly preserved bone strength in animal models of severe immobilization resulting from acute spinal cord injury.

Key Points: 
  • The data demonstrated that NC605, a novel anti-Siglec-15 (S15) antibody, prevented bone loss, but more importantly preserved bone strength in animal models of severe immobilization resulting from acute spinal cord injury.
  • Following spinal cord injury, patients typically suffer rapid and extensive bone loss.
  • While anti-resorptive therapies have shown some efficacy in inhibiting bone loss, these agents also inhibit bone formation.
  • Blood and bone structure analyses revealed that the anti-S15 antibody was able to greatly inhibit bone resorption while maintaining bone formation and quality.

Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development

Retrieved on: 
Tuesday, November 14, 2023

“Today, after over a year of steadfast transformation and execution, Entera stands as a premier oral peptide company.

Key Points: 
  • “Today, after over a year of steadfast transformation and execution, Entera stands as a premier oral peptide company.
  • We are also exploring the potential use of EB613 to accelerate stress fracture healing due to high intensity athletic or military training.
  • Entera Q3 2023 Updates and Goals for 5 Oral Peptide Programs:
    EB613 (oral PTH (1-34), teriparatide), is being developed as the first oral, osteoanabolic (bone building) once-daily tablet treatment for osteoporosis.
  • Entera published pre-clinical data in May 2023 demonstrating that its oral peptide delivery platform enables gastric absorption of teduglutide, as a convenient potential tablet alternative to daily injections.

Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosis

Retrieved on: 
Thursday, November 9, 2023

“This submission is critical to the future of osteoporosis drug innovation which has been hampered by ethical and cost constraints associated with fracture outcome studies.

Key Points: 
  • “This submission is critical to the future of osteoporosis drug innovation which has been hampered by ethical and cost constraints associated with fracture outcome studies.
  • We would like to sincerely acknowledge and thank the ASBMR-FNIH-SABRE team for its significant contributions and for furthering this key initiative with the FDA,” said Miranda Toledano, Chief Executive Officer of Entera.
  • “The last 15 months have been intense for Entera from a regulatory standpoint, and we believe EB613 stands as the first program to potentially avail itself of the ASBMR-SABRE BMD endpoint.
  • EB613 (oral PTH (1-34), teriparatide), is being developed as the first oral, osteoanabolic (bone building) once-daily tablet treatment for osteoporosis.

Boise Cascade Moves Distribution Location to Modesto, CA

Retrieved on: 
Wednesday, November 8, 2023

Boise Cascade Company’s (NYSE: BCC) Building Materials Distribution (BMD) division announced today that it has completed the purchase of a 20-acre property in Modesto, CA.

Key Points: 
  • Boise Cascade Company’s (NYSE: BCC) Building Materials Distribution (BMD) division announced today that it has completed the purchase of a 20-acre property in Modesto, CA.
  • The Company’s current operations in Lathrop, CA, will relocate to this new facility, which includes office space and 190,000 sq.
  • ft. enclosed warehouse served by rail.
  • “We are very excited to join the Modesto community,” said Bill Carr, Branch Manager.

Ultragenyx Reports Third Quarter 2023 Financial Results and Corporate Update

Retrieved on: 
Thursday, November 2, 2023

NOVATO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today reported its financial results for the quarter ended September 30, 2023 and provided its financial guidance for the year.

Key Points: 
  • For the full year 2023, the company expects:
    Crysvita revenue in the range of $325 million to $340 million.
  • This includes all regions where Ultragenyx will recognize revenue, including the royalties in Europe, which have been ongoing, and the royalties in North America, which began in April 2023.
  • In May 2023, Ultragenyx announced the last patient had been dosed in the Phase 3 study.
  • ET to discuss the third quarter 2023 financial results and provide a corporate update.

Ractigen Presents Preclinical Results of Its saRNA Therapeutic Targeting DMD/BMD at the Oligonucleotide Therapeutics Society (OTS) Annual Meeting

Retrieved on: 
Thursday, November 2, 2023

JIANGSU, China, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Ractigen Therapeutics, a clinical stage biopharmaceutical company founded by the pioneers in RNA activation (RNAa), presented recent preclinical results at the annual meeting of the Oligonucleotide Therapeutics Society (OTS) in Barcelona, Spain.

Key Points: 
  • JIANGSU, China, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Ractigen Therapeutics, a clinical stage biopharmaceutical company founded by the pioneers in RNA activation (RNAa), presented recent preclinical results at the annual meeting of the Oligonucleotide Therapeutics Society (OTS) in Barcelona, Spain.
  • RNAa uses short duplex RNA known as saRNA to target and ‘turn up’ transcription of endogenous genes leading to restoration of their protein function.
  • "We are very excited about the preclinical results of our utrophin activating saRNA and believe that our approach could represent an ideal therapeutic strategy that benefits all DMD and BMD patients," said Long-Cheng Li, CEO of Ractigen Therapeutics.
  • The SCADTM platform has propelled Ractigen’s leading RNA program to the clinic for the treatment of ALS patients with SOD1 mutation.